Pulmonary embolism, coagulation
| Zeile 20: | Zeile 20: | ||
*[https://townhall.com/tipsheet/leahbarkoukis/2020/05/05/doctors-are-noticing-a-dangerous-phenomenon-even-after-wuhan-coronavirus-symptoms-are-gone-n2568192 thrombotic late reactions] | *[https://townhall.com/tipsheet/leahbarkoukis/2020/05/05/doctors-are-noticing-a-dangerous-phenomenon-even-after-wuhan-coronavirus-symptoms-are-gone-n2568192 thrombotic late reactions] | ||
| − | + | *'''papers on various thromboembolic maifestations''' | |
| − | + | ||
| − | + | ||
{{tp|p=32281926|t=2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) |pdf=|usr=}} | {{tp|p=32281926|t=2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32347323|t=ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation |pdf=|usr=}} | {{tp|p=32347323|t=ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation |pdf=|usr=}} | ||
| − | + | {{tp|p=32360371|t=ä. Thromboembolic events in patients with SARS-CoV-2 |pdf=|usr=}} | |
| − | + | {{tp|p=C7146714|t=ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 |pdf=|usr=}} | |
| − | + | {{tp|p=32324101|t=2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands |pdf=|usr=}} | |
| − | + | {{tp|p=32133825|t=2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19 |pdf=|usr=}} | |
| + | {{tp|p=32402423|t=2020. Ten key points that vascular doctors learned very quickly about COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32381264|t=2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis |pdf=|usr=}} | ||
| + | {{tp|p=32388068|t=2020. Thrombotic complications in critically ill patients with COVID 19 |pdf=|usr=}} | ||
| + | {{tp|p=32291094|t=2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 |pdf=|usr=}} | ||
| Zeile 45: | Zeile 39: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 105: | Zeile 86: | ||
{{tp|p=32367749|t=2020. Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia |pdf=|usr=}} | {{tp|p=32367749|t=2020. Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia |pdf=|usr=}} | ||
| − | + | ||
| Zeile 115: | Zeile 96: | ||
| − | + | ||
{{tp|p=32283877|t=2020. Prognostic value of myocardial injury in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32283877|t=2020. Prognostic value of myocardial injury in patients with COVID-19 |pdf=|usr=}} | ||
| Zeile 130: | Zeile 111: | ||
| − | + | ||
| Zeile 141: | Zeile 122: | ||
{{ttp|p=32403033|t=2020. Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid |pdf=|usr=}} | {{ttp|p=32403033|t=2020. Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
Version vom 11. Juni 2020, 10:40 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
Since there are many organ manifestations of Hypercoagulation, subcategorization and tranccategorization was applied.
- Venous thrombosis
- Pulmonary embolism
- Cerebral embolism
- Myocardial infarction
- Arterial embolism
- Microembolism
- Hypercoagulation
- Antiphospholipid antibodies
- Disseminated intravascular coagulation
- Bleeding
- Labwork of Thrombembolism
- Prophylaxis of Thrombembolism
The unifying concept behind is Dysendoheliosis with the components Coagulation /Microthrombi, proliferative or cytopathic obstructive Endotheliosis and mediator production as well as failure of the mitigating systems and secondary vasculitis.
- papers on various thromboembolic maifestations
32281926 2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)
32347323 ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation
32360371 ä. Thromboembolic events in patients with SARS-CoV-2
C7146714 ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32324101 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands
32133825 2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19
32402423 2020. Ten key points that vascular doctors learned very quickly about COVID-19
32381264 2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis
32388068 2020. Thrombotic complications in critically ill patients with COVID 19
32291094 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32338320 ä. Covid-19 treatment update: follow the scientific evidence
| 32369610 2020. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily |
32333579 2020. (clin-hemorheol-microcirc) COVID-19
| 32294809 2020. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis |
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32359410 ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT
32367749 2020. Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia
32374544 2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives
32378030 ä. COVID-19-Related Stroke
32283877 2020. Prognostic value of myocardial injury in patients with COVID-19
C7177114 2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes
32376101 2020. Association Between Hypoxemia and Mortality in Patients With COVID-19
32407937 2020. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China
| 32403033 2020. Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid |
